Icosavax

Year Founded: 2018

Similar Companies Hiring

Professional Services • Healthtech • Consulting • Artificial Intelligence • Analytics
Bellevue, WA
13000 Employees
Pharmaceutical • Natural Language Processing • Machine Learning • Healthtech • Biotech • Artificial Intelligence
US
121990 Employees
Software • Pharmaceutical • Healthtech
Seattle, WA
64000 Employees

Icosavax is focused on developing safe and effective vaccines against infectious diseases that cause severe, life-threatening respiratory illnesses. Icosavax is advancing VLP vaccine candidates against respiratory syncytial virus (RSV), human metapneumoviru­­s (hMPV), and SARS-CoV-2 (COVID-19). These vaccine candidates have shown induction of high and durable neutralizing antibody titers in preclinical studies and could protect the most vulnerable populations, including older adults. Icosavax was founded on breakthrough computationally designed VLP technology developed at the Institute for Protein Design. Icosavax exclusively licensed the technology for use in several vaccine fields from the University of Washington. For SARS-CoV-2, Icosavax has a worldwide license with an exclusive option for IVX-411 in North America and Europe from the University of Washington. Icosavax is located in Seattle.